Why Scientists Are Rethinking the Chemical “Arms Race” Against Fungi
Context
Scientists are increasingly concerned about the emergence of antifungal resistant pathogens, particularly Candida auris. Recent research suggests that fungi can develop resistance not only through genetic mutations but also through mechanisms such as increased copies of protective genes. This is challenging conventional approaches to antifungal treatment and highlighting the need for new strategies.
Key Highlights
- Candida auris is an emerging fungal pathogen that can cause serious bloodstream and other infections, particularly among hospitalised and immunocompromised patients.
- The fungus has developed resistance to commonly used antifungal medicines, including azoles and echinocandins, making some infections more difficult to treat and increasing concerns about healthcare associated transmission.
- Research suggests that genetic changes, including additional copies of specific genes, can strengthen fungal defence mechanisms and help the organism survive exposure to antifungal drugs.
- Climate change may influence fungal ecology. Rising temperatures could favour the adaptation of certain fungi to conditions closer to the human body temperature, potentially increasing their ability to infect humans.
- The growing evidence indicates that relying only on an escalating drug based approach may not be sufficient. Future antifungal strategies may require combination therapies, new molecular targets, genomic surveillance and personalised treatment.
Key Concepts
- Antifungal Resistance: The ability of fungi to survive or continue growing despite exposure to antifungal medicines that would normally inhibit or eliminate them.
- Candida auris: An emerging pathogenic yeast associated particularly with healthcare settings and capable of causing invasive infections that can be difficult to treat.
- Azoles: A major group of antifungal medicines that interfere with the production of ergosterol, an important component of fungal cell membranes.
- Echinocandins: Antifungal medicines that target fungal cell wall synthesis and are commonly used to treat invasive Candida infections.
Way Forward
The focus should shift from relying exclusively on a drug versus pathogen approach towards a combination of therapies, genomic surveillance, rapid diagnostic tools and the identification of new molecular targets. Strong infection control and surveillance measures are also essential to limit the spread and emergence of antifungal resistant pathogens.